The patent includes pharmaceutical compositions, methods of treatment, and combination kits. The patent applies to the use of Xyfid as well as to a range of methods designed to protect body tissue from the toxic effects of certain systemically administered anticancer therapeutic agents.
Michael Becker, president and CEO of VioQuest, said: “The Xyfid patent further positions VioQuest to advance clinical programs involving Xyfid and new research involving a range of methods to address toxicity issues for patients treated with anticancer therapies in the years ahead.”